COVID-19: 'Pandemic-ready' set-up placing Emergent apart in CDMO Space

07.29.2020

In a recent article with BioProcess International, Syed T. Husain, senior vice president & CDMO business unit head at Emergent BioSolutions, discusses the critical role Emergent has in supporting the development & manufacturing of COVID-19 vaccine candidates.

Read the full article here.

Emergent CDMO

COVID-19 Thought Leadership

04.27.2020

Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for Johnson & Johnson’s Lead Vaccine Candidate for COVID-19

GAITHERSBURG, Md., April 23, 2020 (GLOBE NEWSWIRE)

Emergent BioSolutions Inc. (NYSE:EBS) today announced an agreement whereby...

READ MORE

06.01.2020

Emergent BioSolutions Joins U.S. Government’s Warp Speed Program in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and Manufacturing

Emergent and HHS expand 2012 CIADM public-private partnership with task order valued at approximately $628 million for rapid...

READ MORE

09.14.2021

Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B

Total baseline value for Emergent is approximately $90 million USD, further expanding the collaboration between the companies,...

READ MORE